Read about agents targeting metastasis in our March 2019 issue

Latest Reviews

  • Review Article |

    The majority of genetically targeted approaches to cancer therapy focus on somatic mutations. However, evidence is accumulating in support of a role for germline genetic alterations in determining responsiveness to treatment. In this Review, the authors summarize the therapeutic potential of knowledge of the germline genome in patients with cancer.

    • Subotheni Thavaneswaran
    • , Emma Rath
    • , Kathy Tucker
    • , Anthony M. Joshua
    • , Dominique Hess
    • , Mark Pinese
    • , Mandy L. Ballinger
    •  & David M. Thomas
  • Consensus Statement | | open

    Brain cancer encompasses a diverse range of complex malignancies, many of which are associated with a poor prognosis and require more effective treatments. In this Position Paper, an international panel of clinicians and laboratory-based scientists convened by Cancer Research UK identify and discuss seven challenges that must be overcome if we are to cure all patients with a brain tumour.

    • Kenneth Aldape
    • , Kevin M. Brindle
    • , Louis Chesler
    • , Rajesh Chopra
    • , Amar Gajjar
    • , Mark R. Gilbert
    • , Nicholas Gottardo
    • , David H. Gutmann
    • , Darren Hargrave
    • , Eric C. Holland
    • , David T. W. Jones
    • , Johanna A. Joyce
    • , Pamela Kearns
    • , Mark W. Kieran
    • , Ingo K. Mellinghoff
    • , Melinda Merchant
    • , Stefan M. Pfister
    • , Steven M. Pollard
    • , Vijay Ramaswamy
    • , Jeremy N. Rich
    • , Giles W. Robinson
    • , David H. Rowitch
    • , John H. Sampson
    • , Michael D. Taylor
    • , Paul Workman
    •  & Richard J. Gilbertson
  • Review Article |

    The advent of effective molecularly targeted treatments and immunotherapies for non-small-cell lung cancer (NSCLC) has greatly improved patient outcomes. Whereas most patients selected for treatment with molecularly targeted drugs derive benefits from these agents, benefit from immunotherapy is more difficult to predict. Herein, Camidge and colleagues compare and contrast predictive biomarkers for immunotherapy and targeted therapy of NSCLC to highlight considerations for biomarker development.

    • D. Ross Camidge
    • , Robert C. Doebele
    •  & Keith M. Kerr
  • Review Article |

    The development of more-targeted cancer therapies has not been matched by more-targeted imaging methods. This discrepancy has, in some scenarios, resulted in inaccurate assessments of the effects of novel therapies. In this Review, the authors describe potential novel imaging approaches that could be adopted to enable improvements in imaging-based monitoring of treatment responses and resistance.

    • Mirjam Gerwing
    • , Ken Herrmann
    • , Anne Helfen
    • , Christoph Schliemann
    • , Wolfgang E. Berdel
    • , Michel Eisenblätter
    •  & Moritz Wildgruber
  • Review Article |

    Regulatory T (Treg) cells are implicated in cancer immune evasion and escape and thus contribute to tumour development and progression. In this Review, the authors provide an overview of the phenotypes and roles of Treg cells in the context of cancer and outline potential strategies to target this cell type in anticancer immunotherapy.

    • Yosuke Togashi
    • , Kohei Shitara
    •  & Hiroyoshi Nishikawa
  • Review Article |

    In the past few years, the use of data from the real world has garnered increasing interest; however, studies using real-world data (RWD) should not be used as substitutes for clinical trials. The authors of this Review explore the quality of RWD, provide a framework for the use of RWD and draw attention to the methodological pitfalls inherent to using RWD.

    • Christopher M. Booth
    • , Safiya Karim
    •  & William J. Mackillop

News & Comment

Naturejobs.com

Nature events Directory